Search

Your search keyword '"Schäfer‐Eckart, K."' showing total 179 results
Start Over Author "Schäfer‐Eckart, K."
179 results on '"Schäfer‐Eckart, K."'

2. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

Author

Röllig, C., Kramer, M., Gabrecht, M., Hänel, M., Herbst, R., Kaiser, U., Schmitz, N., Kullmer, J., Fetscher, S., Link, H., Mantovani-Löffler, L., Krümpelmann, U., Neuhaus, T., Heits, F., Einsele, H., Ritter, B., Bornhäuser, M., Schetelig, J., Thiede, C., Mohr, B., Schaich, M., Platzbecker, U., Schäfer-Eckart, K., Krämer, A., Berdel, W.E., Serve, H., Ehninger, G., and Schuler, U.S.

Published
2018
Full Text
View/download PDF

9. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

Author

Müller-Tidow, C, Tschanter, P, Röllig, C, Thiede, C, Koschmieder, A, Stelljes, M, Koschmieder, S, Dugas, M, Gerss, J, Butterfaß-Bahloul, T, Wagner, R, Eveslage, M, Thiem, U, Krause, S W, Kaiser, U, Kunzmann, V, Steffen, B, Noppeney, R, Herr, W, Baldus, C D, Schmitz, N, Götze, K, Reichle, A, Kaufmann, M, Neubauer, A, Schäfer-Eckart, K, Hänel, M, Peceny, R, Frickhofen, N, Kiehl, M, Giagounidis, A, Görner, M, Repp, R, Link, H, Kiani, A, Naumann, R, Brümmendorf, T H, Serve, H, Ehninger, G, Berdel, W E, and Krug, U

Published
2016
Full Text
View/download PDF

10. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

Author

Middeke, J M, Herbst, R, Parmentier, S, Bug, G, Hänel, M, Stuhler, G, Schäfer-Eckart, K, Rösler, W, Klein, S, Bethge, W, Bitz, U, Büttner, B, Knoth, H, Alakel, N, Schaich, M, Morgner, A, Kramer, M, Sockel, K, von Bonin, M, Stölzel, F, Platzbecker, U, Röllig, C, Thiede, C, Ehninger, G, Bornhäuser, M, and Schetelig, J

Published
2016
Full Text
View/download PDF

11. P545: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19

Author

Kayser, S., primary, Martínez-Cuadrón, D., additional, Rodriguez-Veiga, R., additional, Hänel, M., additional, Tormo, M., additional, Schäfer-Eckart, K., additional, Botella, C., additional, Stölzel, F., additional, Bernal del Castillo, T., additional, Keller, U., additional, Rodriguez-Medina, C., additional, Held, G., additional, Amigo, M.-L., additional, Schliemann, C., additional, Colorado, M., additional, Kaufmann, M., additional, Barrios Garcia, M., additional, Krause, S. W., additional, Görner, M., additional, Jost, E., additional, Steffen, B., additional, Ho, A. D., additional, Baldus, C., additional, Serve, H., additional, Platzbecker, U., additional, Müller-Tidow, C., additional, Thiede, C., additional, Bornhäuser, M., additional, Montesinos, P., additional, Röllig, C., additional, and Schlenk, R. F., additional

Published
2022
Full Text
View/download PDF

12. P449: NOVEL, FIRST-IN-CLASS, SOMATIC IDH2 DELETION-INSERTION VARIANT C.516_518DELINSTGC CONFERS BORDERLINE PHENOTYPE AND DOES NOT SHOW SUSCEPTIBILITY TO ENASIDENIB IN-VITRO

Author

Ruhnke, L., primary, Poitz, D. M., additional, Herold, S., additional, Dressler, S., additional, Dill, C., additional, Peitzsch, M., additional, Oelschlägel, U., additional, Frimmel, J., additional, Kunadt, D., additional, Kretschmann, T., additional, Altmann, H., additional, Stölzel, F., additional, Röllig, C., additional, Chavakis, T., additional, Baretton, G., additional, Schäfer-Eckart, K., additional, and Bornhäuser, M., additional

Published
2022
Full Text
View/download PDF

13. Functionalization of scaffolds of bioactive glass (CAR12N) with biodegradable poly(L-lactide) (PLLA) enhances chondrogenesis of mesenchymal stromal cells for cartilage tissue engineering

Author

Gögele, C, Müller, S, Wiltzsch, S, Lenhart, A, Hornfeck, M, Rübling, A, Schäfer-Eckart, K, Minnich, B, Weiger, TM, Schulze-Tanzil, G, Gögele, C, Müller, S, Wiltzsch, S, Lenhart, A, Hornfeck, M, Rübling, A, Schäfer-Eckart, K, Minnich, B, Weiger, TM, and Schulze-Tanzil, G

Published
2022

15. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

Author

Schetelig, J, Schaich, M, Schäfer-Eckart, K, Hänel, M, Aulitzky, W E, Einsele, H, Schmitz, N, Rösler, W, Stelljes, M, Baldus, C D, Ho, A D, Neubauer, A, Serve, H, Mayer, J, Berdel, W E, Mohr, B, Oelschlägel, U, Parmentier, S, Röllig, C, Kramer, M, Platzbecker, U, Illmer, T, Thiede, C, Bornhäuser, M, and Ehninger, G

Published
2015
Full Text
View/download PDF

17. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)†

Author

Thiel, A., Schetelig, J., Pönisch, W., Schäfer-Eckart, K., Aulitzky, W., Peter, N., Schulze, A., Maschmeyer, G., Neugebauer, S., Herbst, R., Hänel, A., Morgner, A., Kroschinsky, F., Bornhäuser, M., Lange, T., Wilhelm, M., Niederwieser, D., Ehninger, G., Fiedler, F., and Hänel, M.

Published
2015
Full Text
View/download PDF

18. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Author

Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, and Ottmann, O G

Published
2013
Full Text
View/download PDF

19. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

Author

Metzelder, S K, Schroeder, T, Finck, A, Scholl, S, Fey, M, Götze, K, Linn, Y C, Kröger, M, Reiter, A, Salih, H R, Heinicke, T, Stuhlmann, R, Müller, L, Giagounidis, A, Meyer, R G, Brugger, W, Vöhringer, M, Dreger, P, Mori, M, Basara, N, Schäfer-Eckart, K, Schultheis, B, Baldus, C, Neubauer, A, and Burchert, A

Published
2012
Full Text
View/download PDF

20. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)

Author

Kröger, Nicolaus, Einsele, Hermann, Wolff, Daniel, Casper, Jochen, Freund, Mathias, Derigs, Günter, Wandt, Hannes, Schäfer-Eckart, K, Wittkowsky, Georg, Schmitz, Norbert, Krüger, William, Zabelina, Tatjana, Renges, Helmut, Ayuk, Francis, Krüll, Andreas, and Zander, Axel

Published
2003
Full Text
View/download PDF

32. Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia : Results from the SAL-DaunoDouble trial

Author

Röllig, C., Steffen, B., Herbst, R., Noppeney, Richard, Racil, Z., Schäfer-Eckart, K., Krämer, A., Neubauer, A., Baldus, C. D., Schliemann, C., Kaufmann, M., Mertova, J., Jost, E., Niemann, D., Novak, J., Krause, S. W., Scholl, S., Held, G., Parmentier, S., Szotkowski, T., Zak, P., Rank, A., Wass, M., Buske, S., Platzbecker, U., Kramer, M., Schetelig, J., Müller-Tidow, C., Serve, H., Bornhäuser, M., Berdel, W. E., Mayer, J., Ehninger, G., and Studienallianz Leukämie (SAL)

Subjects
Medizin
Published
2018

33. Cardiac toxicity of two anthracycline doses in AML induction : Short term results from the randomized SAL-DaunoDouble trial

Author

Dendorfer, S., Kramer, M., Schmidt-Brücken, K., Stölzel, F., Herbst, R., Noppeney, Richard, Racil, Z., Mayer, J., Steffen, B., Bochtler, T., Krämer, A., Müller-Tidow, C., Schäfer-Eckart, K., Burchert, A., Neubauer, A., Baldus, C. D., Schliemann, C., Kaufmann, M., Jost, E., Naumann, R., Scholl, S., Hochhaus, A., Ehninger, G., Bornhäuser, M., and Röllig, C.

Subjects
Medizin
Published
2018

34. The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival : Updated results from long-term follow-up of the randomized-controlled SORAML trial

Author

Röllig, C., Serve, H., Hüttmann, Andreas, Noppeney, Richard, Müller-Tidow, Carsten, Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., Krämer, A., Schäfer-Eckart, K., Neubauer, A., Burchert, A., Giagounidis, A., Krause, S. W., Mackensen, A., Aulitzky, W., Herbst, R., Hänel, M., Kiani, A., Frickhofen, N., Kullmer, J., Kaiser, U., Link, H., Geer, T., Reichle, A., Junghanß, C., Bornhäuser, M., Schaich, M., Thiede, C., Schetelig, J., Kramer, M., Berdel, W. E., Ehninger, G., and Studienallianz Leukämie (SAL)

Subjects
Medizin
Published
2018

37. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Author

Eichhorst, Barbara F, Fischer, Kirsten, Fink, Anna Maria, Elter, Thomas, Wendtner, Clemens M, Goede, Valentin, Bergmann, Manuela, Stilgenbauer, Stephan, Hopfinger, Georg, Ritgen, Matthias, Bahlo, Jasmin, Busch, Raymonde, Hallek, Michael, Oduncu, F, Dreyling, M, Forstpointner, R, Schneller, F, Bogner, C, Peschel, C, Ringshausen, I, Götze, K, Goebeler, Me, Rückle, Lanz, Ritgen, M, Schawitzke, A, Heydrich, B, Kern, K, Böttcher, S, Irmer, S, Strack, U, Borries, V, Klima, Km, Scholz, C, Herold, M, Härtwig, K, Dürig, J, Dührsen, U, Müller Beissenhirtz, H, Noppeney, R, Schüttrumpf, S, Hohloch, K, Binder, C, Hasenkamp, J, Trümper, L, Bäsecke, J, Rieger, M, Witzens Harig, M, Friedrichs, B, Rieger, K, Uharek, L, Kubuschok, B, Murawski, N, Held, G, Zwick, C, Pfreundschuh, M, Fingerle Rowson, G, Reiser, M, Elter, T, Eichhorst, B, Pallasch, C, Hallek, M, Borchmann, P, Hacker, U, Schinkel, S, Wieker, K, Sökler, M, Wolf, Hh, Eucker, J, Staib, P, Schlegel, F, Kropff, M, Kahl, C, Hess, G, Beck, J, Wölfel, T, Bokemeyer, C, Schilling, G, Dierlamm, J, Schüler, F, Busemann, C, Dölken, G, Trendelenburg, Tk, Bühler, A, Stilgenbauer, S, Viardot, A, Greiner, J, Zenz, T, Gaidzik, V, Langer, C, Döhner, H, Werner, I, Dienst, A, Habersang, K, Härtel, N, Leitner, A, Kehrer, G, Middeke, H, Heinisch, K, Adorf, D, Ismer, B, Hering Schubert, C, Jäckle, J, Aulmann, C, Söllner, S, Majunke, P, Fuss, H, Käfer, G, Potenberg, J, Dietrich, G, Hartung, E, Pronath, A, Riedhammer, Fj, Zehrfeld, T, Prümmer, O, Gatter, J, Meier, A, Wattad, M, Heit, W, Sauer, I, Hilgers, K, Geissler, M, Bauer, J, Stein, W, Voigtmann, R, Natt, F, Nickelsen, M, Zeis, M, Schmitz, N, Lange, E, Stoltefuss, A, Schubert, J, Dürk, Ha, Kloke, O, Fauser, A, Roemer, E, Kraut, L, Musch, E, Kohl, S, Link, H, Kirsch, Jf, Schatz, M, Mezger, J, Kempf, B, Heil, G, Derigs, Hg, Roll, C, Kettner, E, Dübbers, Hw, Lutz, L, Hentrich, M, Hoffmann, U, Ibe, M, Falge, C, Schäfer Eckart, K, Rothmann, F, Raghavachar, A, Beckmann, K, Behringer, D, Stauder, H, Hempfling, C, Matzdorff, A, Hähling, D, Kaesberger, Kj, Mück, R, Waladkhani, Ar, Clemens, M, Kraft, J, Ehlert, T, N. N., Schloen, A, Sandritter, B, Scholz, Diekmann, C, Pflüger, Kh, Hausner, G, Fetscher, S, Aulitzky, W, Brugger, W, Frickhofen, N, Fuhr, Lange, C, Lambertz, H, Schulz, L, Schmier, M, Bentz, M, Tauchmann, Gm, Schmidt, M, Meiler, J, Sandmann, M, Kürschner, D, Maier Bay, B, Lindemann, W, Diers, J, Riemeier Sievers, C, Daun, M, Mergenthaler, Hg, Hiller, S, Schirmer, V, Kirchner, H, Langer, W, Günther, B, Gassmann, W, Franke, K, Burghardt, F, Abele, U, Celikel Becker, D, von Weikersthal LF, Brög, G, Hauch, U, Heinrich, B, Brudler, O, Häcker, B, Eckart, Mj, Bolouri, H, Göttler, B, Kindler, M, Zuchold, K, Strohbach, F, Plingen, Ml, Seibt Jung, H, Kirsch, A, Herrenberger, J, Doering, G, von Grünhagen, U, Franke, H, Weniger, J, Kerzel, W, Schmalfeld, M, Rohrberg, R, Hurtz, Hj, Gehbauer, G, Hahnfeld, S, Vehling Kaiser, U, Abenhardt, W, Bosse, D, Böning, L, Schmidt, B, Schick, Hd, Jacobs, G, Stauch, M, Hoffmann, R, Müller, S, Hahn, M, Freier, W, Dietzfelbinger, H, Rassmann, I, Söling, U, Siehl, S, Rudolph, R, Weinert, R, Sauer, A, Meyer, B, Eschenburg, H, Schadeck Gressel, C, Grabenhorst, U, Perker, M, Otremba, B, Reschke, D, Hinrichs, Hf, Zirpel, I, Höring, E, Respondek, M, Köppler, H, Heymanns, J, Weide, R, Hünermund, K, Thiel, C, Reiber, T, Spohn, C, Springer, G, Fiechtner, H, Hübner, A, Kurschel, E, Weiss, J, Schlag, R, Schäfer, E, Hartwich, G, Schmitz, S, Steinmetz, T, Kim, Ts, Lerchenmüller, C, Wehmeyer, J, Laubenstein, Hp, Rendenbach, B, Lebahn, H, Kröning, H, Uhle, R, Balló, H, Gaede, B, Zumbrink, S, Eckert, R, Kamp, T, Reimann, B, Burkhard, O, Mittermüller, J, Hansen, R, Hitz, H, Schliesser, G, Schmitt, Hr, Forstbauer, H, Grundeis, M, Schulze, M, Baldus, M, Lakner, V, Haen, M, Müller, C, Dörfel, S, Göhler, T, Welslau, M, Achtzehn, V, Culmann, H, Gerhardt, S, Ulshöfer, T, Koschuth, A, Schmidt, P, Müller, L, Schneider, M, Koniczek, K, Porowski, P, Glados, M, Knoblich, J, Ben Yehuda, D, Jäger, U, Gaiger, A, Schwarzmeier, J, Nösslinger, T, Smith, M, Patton, N, Gibbons, S, Bouabdallah, R, Gandhi, M, Marlton, P, Mills, T, Angelucci, E, Sorano, Gg, Casula, P, Berneman, Z, Kohser, P, Hudcova Burgetova, A, Machová, R, Papajik, T, Kubová, Z, Fineman, R, Mayer, J, Doubek, M, Brychtova, Y, Ciceri, F, Caligaris Cappio, F, Crocchiolo, R, Dauriac, C, Bernard, M, Escoffre Barbe, M, Lamy, T, Zikesova, E, Karban, J, Salkova, J, Trnený, M, Pytlik, R, Tiley, C, Forsyth, C, Vokurka, S, Koza, V, Van Hoof, A, Selleslag, D, Sebban, C, Baker, B, Belada, D, Jebavy, L, Smolej, L, Pavel, Z, Di Ianni, M, Castaigne, S, Del Poeta, G, Amadori, S, Catalano, J, Ganju, V, Hertzberg, M, Laurenti, L, Dalseg, Am, Bron, D, Morton, J, Durrant, S, Casado, Lf, Theunissen, K, Atias, D, Berkhan, L, Seymour, J, Wolf, M, Bosly, A, Osma Cordoba MM, Portois, C, Jaubert, J, Ferrant, A, Lambert, C, Maerevoet, E, Van den Neste, E, Gadeberg, O, Carney, B, Cannell, P, Eghbali, H, Legouffe, E, Bordessoule, D, Chaury, M, Moreau, S, Pierri, I, Gobbi, M, Berrebi, A, Lishner, M, Yerushazim, R, Yermiaku, T, Kosolov, V, Ambrosetti, Achille, Andreoli, Al, Huguet, F, Laurent, G, Orsucci, L, Forconi, F, Musuraca, G, Zinzani, Pl, Loscertales, J, Mcquillan, A, Cordingley, F, Leahy, M, Cazin, B, Taylor, Mulligan, S, Herbrecht, Cull, G, Seldon, M, Rowlings, P, Ludwig, H, Zojer, N, Solal Céligny, P, Pomponi, F, Savdkova, L, Kozák, T, Christiansen, I, Pérez, I, Campbell, P, Canales Albendea, M, De Paz, R, Arthur, C, Gisselbrecht, C., Eichhorst B.F., Fischer K., Fink A.M., Elter T., Wendtner C.M., Goede V., Bergmann M., Stilgenbauer S., Hopfinger G., Ritgen M., Bahlo J., Busch R., Hallek M., and Zinzani P.L.

Subjects
Male, medicine.medical_specialty, Cyclophosphamide, Chronic lymphocytic leukemia, Immunology, Medizin, Antineoplastic Combined Chemotherapy Protocols, Blood Cell Count, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Prognosis, Recurrence, Remission Induction, Tomography, X-Ray Computed, Physical examination, Biochemistry, Chemoimmunotherapy, medicine, Chronic, Tomography, Leukemia, medicine.diagnostic_test, business.industry, B-Cell, Cancer, Cell Biology, Hematology, medicine.disease, Lymphocytic, imaging techniques, X-Ray Computed, Fludarabine, Surgery, chronic lymphocytic leukemia, Radiology, business, Progressive disease, medicine.drug
Abstract

The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.

Published
2011

38. Karyotype complexity and prognosis in acute myeloid leukemia

Author

Stölzel, F, primary, Mohr, B, additional, Kramer, M, additional, Oelschlägel, U, additional, Bochtler, T, additional, Berdel, W E, additional, Kaufmann, M, additional, Baldus, C D, additional, Schäfer-Eckart, K, additional, Stuhlmann, R, additional, Einsele, H, additional, Krause, S W, additional, Serve, H, additional, Hänel, M, additional, Herbst, R, additional, Neubauer, A, additional, Sohlbach, K, additional, Mayer, J, additional, Middeke, J M, additional, Platzbecker, U, additional, Schaich, M, additional, Krämer, A, additional, Röllig, C, additional, Schetelig, J, additional, Bornhäuser, M, additional, and Ehninger, G, additional

Published
2016
Full Text
View/download PDF

41. A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: Planning, expectations and reality

Author

UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service d'hématologie, Labopin, M., Gorin, N.-C., Polge, E., Socié, G., Gurman, G., Gluckman, E., Jindra, P., Poire, Xavier, Schäfer-Eckart, K., Ruutu, T., Milone, G., Arcese, W., Mohty, M., Rocha, V., UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service d'hématologie, Labopin, M., Gorin, N.-C., Polge, E., Socié, G., Gurman, G., Gluckman, E., Jindra, P., Poire, Xavier, Schäfer-Eckart, K., Ruutu, T., Milone, G., Arcese, W., Mohty, M., and Rocha, V.

Abstract

For adults with acute leukemia, it is important to know whether the therapeutic schemes initially planned were actually implemented. The European Group for Blood and Marrow transplantation Acute Leukemia Working Party prospectively followed 695 consecutive patients who were registered at the time of HLA typing. Of 304 patients with an available matched sibling donor (MSD), SCT was planned in 264, chemotherapy in 33 and autografting in 7. For the rest, an unrelated donor (UD) search was initiated in 198. Among these, 117 were transplanted, 114 received chemotherapy and 77 underwent autografting. Probabilities of receiving a planned treatment were 60 and 65% at 1 and 2 years, respectively. Patients scheduled to receive MSD SCT had an 82% probability, whereas those scheduled to undergo UD SCT had a 57% probability, of receiving their transplant at 1 year. The only factor associated with a lower probability of MSD SCT in first remission was delayed HLA typing (HR=0.82; P=0.03). One year after enrollment, 40% of patients did not follow their initial treatment plan. Because OS was 50% only at 3 years and only 57% of the patients without a MSD underwent SCT, this suggests room for improvement in outcomes for adults with acute leukemia. © 2014 Macmillan Publishers Limited. All rights reserved.

Published
2014

42. Cytoreduction with Alemtuzumab in Patients with Advanced Chronic Lymphocytic Leukemia Prior to Allogeneic Stem Cell Transplantation – Results of a Prospective Clinical Trial (NCT 00337519)

Author

Schetelig, J., primary, Bornhäuser, M., additional, Thiede, C., additional, Platzbecker, U., additional, Mohr, B., additional, Oelschlägel, U., additional, Hänel, M., additional, Schwerdtfeger, R., additional, Kolbe, K., additional, Kaufmann, M., additional, Zeis, M., additional, and Schäfer-Eckart, K., additional

Published
2012
Full Text
View/download PDF

43. An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission

Author

Bornhauser, Martin, primary, Kienast, Joachim, additional, Trenschel, Rudolf, additional, Burchert, Andreas, additional, Hegenbart, Ute, additional, Stadler, Michael, additional, Baurmann, Herrad, additional, Schäfer-Eckart, K., additional, Holler, Ernst, additional, Kröger, Nicolaus, additional, Schmid, Christoph, additional, Einsele, Hermann, additional, Kiehl, Michael, additional, Schwerdtfeger, Rainer, additional, Ganser, Arnold, additional, Dreger, Peter, additional, Neubauer, Andreas, additional, Berdel, Wolfgang E., additional, Ehninger, Gerhard, additional, Beelen, Dietrich, additional, Schetelig, Johannes, additional, and Stelljes, Matthias, additional

Published
2011
Full Text
View/download PDF

44. Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Author

Pfeifer, Heike, primary, Goekbuget, Nicola, additional, Völp, Christian, additional, Hüttmann, Andreas, additional, Lübbert, Michael, additional, Stuhlmann, Reingard, additional, Dengler, Julanta, additional, Kreuzer, Karl-Anton, additional, Beck, Joachim, additional, Stelljes, Matthias, additional, Schmid, Mathias, additional, Wassmann, B., additional, Leimer, Lothar, additional, Spiekermann, Karsten, additional, Terwey, Theis H, additional, Schäfer-Eckart, K., additional, Ditz, D., additional, Lindemann, H., additional, Morgner, A., additional, Schaich, Markus, additional, Burmeister, Thomas, additional, Binckebanck, A., additional, Hoelzer, Dieter, additional, and Ottmann, Oliver G., additional

Published
2010
Full Text
View/download PDF

47. Phase II Multicenter Trial To Evaluate the Safety and Efficacy of Low-Toxicity Treosulfan/Fludarabine Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.

Author

Holowiecki, Jerzy, Giebel, S., Beelen, D., Trenschel, R., Wandt, H., Schaefer-Eckart, K., Ruutu, T., Volin, L., Einsele, H., Stuhler, G., Uharek, L., Blau, I., Bornhaeuser, M., Zander, A., Kroeger, N., Aschan, J., Wojnar, J., Markiewicz, M., Freund, M., and Casper, J.

Published
2007
Full Text
View/download PDF

49. Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia.

Author

Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf TH, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JMM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, and Röllig C

Abstract

In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570 newly diagnosed AML patients (median age, 56 years) treated with cytarabine-based intensive chemotherapy regimens. As compared to the 2017 ELN classification (ELN17), allocating 595 (38%), 413 (26%) and 562 (36%) patients to the favorable, intermediate and adverse risk category, ELN22 risk was favorable, intermediate, and adverse in 575 (37%), 410 (26%), and 585 (37%) patients, respectively. Risk group allocation was revised in 340 patients (22%). Most patients were re-classified into ELN22 intermediate or ELN22 adverse risk group. The allocation of patients according to the ELN22 risk categories resulted in a significantly distinct event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS). As compared to ELN17, reallocation according to the ELN22 recommendations resulted in a significantly improved prognostic discrimination for OS (3-year area under the curve (AUC) 0.71 vs. 0.67). In patients with ELN22 favorable risk AML, co-occurring MR gene mutations did not significantly impact outcome. Within the ELN22 adverse risk group, we observed marked survival differences across mutational groups (5-year OS rate of 21% and 3% in patients with myelodysplasia-related (MR) gene mutations and TP53-mutated patients, respectively). In patients harboring MR gene mutations, EZH2-, STAG2- and ZRSR2-mutated patients showed an intermediate-like OS. In patients with secondary AML and those who underwent allogeneic HCT, EFS and OS significantly differed between ELN22 risk groups, while prognostic abilities of ELN17 and ELN22 classifications were similar. In conclusion, the ELN22 risk stratification improves prognostic discrimination in a large cohort of intensively treated AML patients. Given the heterogeneous outcome in patients with MR gene alterations, ranging between those of intermediate and adverse risk patients, we suggest reevaluation of risk allocation in these patients., (Copyright © 2024 American Society of Hematology.)

Published
2024
Full Text
View/download PDF

50. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study).

Author

Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kröger N, Ayuk FA, Stoelzel F, Middeke JM, Eder M, Bethge W, Finke J, Bertz H, Kobbe G, Kaufmann M, Platzbecker U, Beverungen D, Schmid C, von Bonin M, Egger-Heidrich K, Heberling L, Trautmann-Grill K, Teipel R, Bug G, Tischer J, Fraccaroli A, Fante M, Wolff D, Luft T, Winkler J, Schäfer-Eckart K, Scheid C, Holtick U, Klein S, Blau IW, Burchert A, Wulf G, Hasenkamp J, Schwerdtfeger R, Kaun S, Junghanss C, Wortmann F, Winter S, Neidlinger H, Theuser C, Beyersmann J, Bornhaeuser M, Schmeller S, and Schetelig J

Subjects
Humans, Female, Pregnancy, Adult, Young Adult, Adolescent, Registries, Transplantation, Homologous, Infant, Newborn, Live Birth, Pregnancy Outcome, Transplantation Conditioning methods, Hematopoietic Stem Cell Transplantation
Abstract

Abstract: Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy and birth rates in a contemporary cohort, we conducted a national multicenter study using data from the German Transplant Registry, focusing on adult women aged 18 to 40 years who underwent alloHCT between 2003 and 2018. Of 2654 women who underwent transplantation, 50 women experienced 74 pregnancies, occurring at a median of 4.7 years after transplant. Fifty-seven of these resulted in live births (77%). The annual first birth rate among HCT recipients was 0.45%, which is >6 times lower than in the general population. The probability of a live birth 10 years after HCT was 3.4%. Factors associated with an increased likelihood of pregnancy were younger age at alloHCT, nonmalignant transplant indications, no total body irradiation or a cumulative dose of <8 Gy, and nonmyeloablative/reduced-intensity conditioning. Notably, 72% of pregnancies occurred spontaneously, with assisted reproductive technologies used in the remaining cases. Preterm delivery and low birth weight were more common than in the general population. This study represents the largest data set reporting pregnancies in a cohort of adult female alloHCT recipients. Our findings underscore a meaningful chance of pregnancy in alloHCT recipients. Assisted reproductive technologies techniques are important and funding should be made available. However, the potential for spontaneous pregnancies should not be underestimated, and patients should be informed of the possibility of unexpected pregnancy despite reduced fertility. Further research is warranted to understand the impact of conditioning decisions on fertility preservation., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results